Indefinite Delivery Contract SPE2DX16D9927
- Not listed
- The federal Indefinite Delivery Contract (IDC) awarded to DMS Pharmaceutical Group Inc. by the Defense Logistics Agency (DLA) under the SPE2DB program is a single-award contract valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply...
- This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including...
- This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including...
- This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The $499,999,999 contract, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of branded and generic...
- This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award IDC, valued at $499,999,999, covers the delivery of a comprehensive range of pharmaceutical products to support the recurring medical supply needs of military healthcare facilities worldwide. The contract enables the DLA to issue firm fixed-price delivery orders for branded and generic prescription...
- This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including...
- This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The single-award IDC, valued at $499,999,999 and valid through November 2026, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive...
- This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award IDC, valued at $499,999,999 and valid through November 2026, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of...
- This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including...
- This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The single-award IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical...
The Indefinite Delivery Contract (IDC) awarded to DMS Pharmaceutical Group Inc. by the Defense Logistics Agency (DLA) under the SPE2DX program is a single-award contract valued at $499,999,999 and valid through November 2026. This contract enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The contract covers various product categories such as injections, tablets, creams, auto-injectors, and specialty medications, positioning DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain. The contract is not associated with any set-aside designations, allowing the woman-owned small business to leverage its status to secure direct federal awards across multiple product categories and medical domains. Through this IDC, DMS Pharmaceutical Group provides direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites, demonstrating its capability to meet the recurring medical supply needs of the military.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $0 | 4/5/16 |